TNYA
Tenaya Therapeutics, Inc.
Key Financials
Revenue
$225000
N/A
Net Income
$-90597000
↑ 18.5%
Total Liabilities
$23.7M
↓ 12.7%
Shareholders' Equity
$123.3M
↑ 32.8%
EPS (Diluted)
$-0.59
↑ 55.0%
Cash & Equivalents
$100.5M
↑ 2225.9%
Total Assets
$146.9M
↑ 22.5%
Operating Income
$-93331000
↑ 19.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 5/19/2026 | View on SEC |
| 4 | 5/19/2026 | View on SEC |
| 4 | 5/19/2026 | View on SEC |
| 10-Q | 5/6/2026 | View on SEC |
| 8-K | 5/6/2026 | View on SEC |
| ARS | 4/16/2026 | View on SEC |
| DEFA14A | 4/16/2026 | View on SEC |
| DEF 14A | 4/16/2026 | View on SEC |
| 10-K | 3/11/2026 | View on SEC |
| 8-K | 3/11/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TNYA |
| Company Name | Tenaya Therapeutics, Inc. |
| CIK | 1858848 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 415-865-2066 |